BWXT Commercial Operations Names Monifa Miller as Senior Director of Corporate Affairs
(CAMBRIDGE, ON – February 13, 2023) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Monifa A. Miller as senior director of corporate affairs for BWXT’s Commercial Operations segment. In this role, she will have full responsibility for all of BWXT’s communications, public affairs, government relations and community outreach activities in Canada.
BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone
(Ottawa, Ontario – February 1, 2023) – Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear Generating Station, thanks to the installation and initial commissioning of an innovative isotope system by Laurentis Energy Partners and BWXT Medical Ltd. (NYSE: BWXT).
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.
BWXT Promotes Chip Whitford to Senior Vice President and General Counsel
BWX Technologies, Inc. (NYSE: BWXT) has promoted Ronald O. (Chip) Whitford, Jr. to the position of senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 2, 2023.
BWXT Names Omar Meguid Chief Digital Officer
BWX Technologies, Inc. (NYSE: BWXT) has named Omar Meguid as senior vice president and chief digital officer effective January 1, 2023.
BWXT Starts Production of TRISO Fuel for First U.S. Generation IV Microreactor
BWX Technologies, Inc. (NYSE: BWXT) today with officials from the U.S. Department of Defense, Department of Energy, NASA and Idaho National Laboratory celebrated the landmark production of TRISO nuclear fuel that will power the first microreactor built and operated in the United States.
BWX Technologies Reports Third Quarter 2022 Results
LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported third quarter 2022 GAAP net income attributable to BWXT of $61.6 million, or diluted earnings per share (EPS) of $0.67, on revenue of $523.7 million. Third quarter 2022 non-GAAP(1) net income attributable to BWXT was $63.0 million, or $0.69 diluted EPS. Third quarter 2022 adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA)(1) was $100.1 million. A reconciliation of non-GAAP results are detailed in Exhibit 1.
BWXT Closes Amended and Restated Credit Agreement
(LYNCHBURG, Va. – Oct. 12, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that it has closed on an amended and restated credit agreement with Wells Fargo Bank, N.A. and other lenders that increases the company’s liquidity while improving a number of key terms for BWXT.
BWX Technologies to Announce Third Quarter 2022 Results on Monday, November 7
LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (BWXT) (NYSE: BWXT) will issue a press release detailing third quarter 2022 results on Monday, November 7, 2022, after market close and will host a conference call at 5:00 p.m. EST.
BWXT Medical Submits Tc-99m Generator New Drug Application to FDA
Company Highlights Growing Nuclear Medicine Product Portfolio and Future Opportunities in Therapeutic Radioisotopes